A novel approach to the design of potent bioactive peptides by incorporation of proline brackets: antiplatelet effects of Arg-Gly-Asp peptides
- 13 November 1995
- journal article
- research article
- Published by Wiley in FEBS Letters
- Vol. 375 (1-2) , 15-17
- https://doi.org/10.1016/0014-5793(95)01144-4
Abstract
Enhancing the potency of peptides is a critical and important step in the development of peptide drugs. We have proposed that proline residues flanking protein-protein interaction sites perform a structural role in enhancing their interaction [R.M. Kini and H.J. Evans, Biochem. Biophys. Res. Commun. 212 (1995) 1115–1124]. To test this theory, we incorporated proline residues on either or both sides of the interaction site of an antiplatelet peptide, IARGDMNA and determined the inhibitory potency of the peptides in whole blood aggregation. Inclusion of one proline residue, on either the amino or carboxy terminal side of the interaction site, enhances the antiplatelet activity to approximately the same extent (1.5- to 2.5-fold). Incorporation of proline residues on both sides enhances the activity by 7- to 13-fold. This enhancement of the biological activity of the peptide is probably due to a reduction in the number of possible conformations of the peptide, without introducing the rigidity that would accompany cyclization. Incorporation of proline brackets thus provides a novel approach to the design and development of more potent peptide drugs and ligandsKeywords
This publication has 14 references indexed in Scilit:
- The electronic aggregometer: A novel device for assessing platelet behavior in bloodPublished by Elsevier ,2002
- A Hypothetical Structural Role for Proline Residues in the Flanking Segments of Protein-Protein Interaction SitesBiochemical and Biophysical Research Communications, 1995
- Effects of Hybrid Peptide Analogs to Receptor Recognition Domains on α- and γ-Chains of Human Fibrinogen on Fibrinogen Binding to PlateletsThrombosis and Haemostasis, 1993
- Ligand Binding to GPIIb-IIIa: A Status ReportSeminars in Thrombosis and Hemostasis, 1992
- Structural domains in venom proteins: Evidence that metalloproteinases and nonenzymatic platelet aggregation inhibitors (disintegrins) from snake venoms are derived by proteolysis from a common precursorToxicon, 1992
- Platelet receptor recognition domains on the .alpha. chain of human fibrinogen: structure-function analysisBiochemistry, 1989
- Trigramin: primary structure and its inhibition of von Willebrand factor binding to glycoprotein IIb/IIIa complex on human plateletsBiochemistry, 1989
- Fibrinogen, fibrinogen receptors, and the peptides that inhibit these interactionsBiochemical Pharmacology, 1987
- Blood platelet shape change ABCsTrends in Biochemical Sciences, 1987
- Fibrinogen is the receptor for the endogenous lectin of human plateletsNature, 1981